In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

FTSE 100 Live Monday Review calls for Ofwat overhaul Higher fares lift Ryanair profitBP appoints new chair ...

In a stipulation included in a Joint Motion for Entry of Consent Judgment, the IRS stated that when a church communicates ...

The UK’s drugs regulator is now outsourcing almost 40 per cent of applications to trusted regulatory agencies overseas, as it ...

Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration said Friday.

Isle of Man headquartered RL360 has agreed to pay the Isle of Man Financial Services Authority (IFSA) a total of £1.95m in a civil penalty relating to historic anti-money laundering procedures. II ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...

It is a coordinated effort to kill an industry that helps veterans’ posts keep their doors open and allows small businesses ...

The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Ele­vidys, after three patients died from ...